CD96 is a promising candidate as a leukemic stem cell (LSC)-specific antigen and is expressed on the majority of CD34+CD38− Acute myeloid leukemia (AML) cells, whereas only a few cells in the normal Hematopoietic stem cell (HSC)-enriched population express CD96 weakly [206]. Here, CD38 is linked to acute myeloid leukemia.